US OptionsDetailed Quotes
SGMO250117P2000
- 0.10
- -0.02-16.67%
15min DelayClose Dec 27 16:00 ET
0.10High0.10Low
0.10Open0.12Pre Close256 Volume748 Open Interest2.00Strike Price2.56KTurnover143.06%IV25.78%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type-0.1814Delta0.3070Gamma25.60Leverage Ratio-0.0056Theta-0.0003Rho-4.64Eff Leverage0.0016Vega
Sangamo Therapeutics Stock Discussion
Sign in to post a comment
$Sangamo Therapeutics (SGMO.US)$
Should be interesting to see what we get in up front. It's been given Accelerated Approval by FDA so BLA will be filed next year sometime once we get final patient data. I'm guessing 100 to 200 million up front.
Should be interesting to see what we get in up front. It's been given Accelerated Approval by FDA so BLA will be filed next year sometime once we get final patient data. I'm guessing 100 to 200 million up front.
$Sangamo Therapeutics (SGMO.US)$ lets see how it goes. W pattern maybe.
2
$Sangamo Therapeutics (SGMO.US)$ net outflow, rid off weak holders, yet price holding up well. in the watch list for dip picking.
$Sangamo Therapeutics (SGMO.US)$
The STAC-BBB capsid technology addresses one of gene therapy's most challenging obstacles - crossing the blood-brain barrier efficiently. Traditional AAV vectors struggle with CNS penetration, often requiring invasive direct administration. An effective IV-delivered solution could revolutionize neurological gene therapy by enabling broader distribution and simplified administration.
The non-human primate data showing potent BBB ...
The STAC-BBB capsid technology addresses one of gene therapy's most challenging obstacles - crossing the blood-brain barrier efficiently. Traditional AAV vectors struggle with CNS penetration, often requiring invasive direct administration. An effective IV-delivered solution could revolutionize neurological gene therapy by enabling broader distribution and simplified administration.
The non-human primate data showing potent BBB ...
7
$Sangamo Therapeutics (SGMO.US)$
The $20 million upfront payment and potential $1.3 billion in milestone payments represent a significant cash infusion for Sangamo, whose current market cap is around $486 million. The deal structure, with tiered mid-to-high single-digit royalties, follows industry standards for early-stage biotech licensing agreements. The immediate cash boost strengthens Sangamo's balance sheet and extends their operational runway.
The agreement's va...
The $20 million upfront payment and potential $1.3 billion in milestone payments represent a significant cash infusion for Sangamo, whose current market cap is around $486 million. The deal structure, with tiered mid-to-high single-digit royalties, follows industry standards for early-stage biotech licensing agreements. The immediate cash boost strengthens Sangamo's balance sheet and extends their operational runway.
The agreement's va...
2
$Sangamo Therapeutics (SGMO.US)$
Sangamo Therapeutics (SGMO) shares were up over 15% amid a license deal granting Astellas Pharma worldwide rights to its neurotropic adeno-associated virus capsid, STAC-BBB, for neurological disease targets, the companies said. The consideration for the deal includes a $20 million upfront license payment.
Sangamo Therapeutics (SGMO) shares were up over 15% amid a license deal granting Astellas Pharma worldwide rights to its neurotropic adeno-associated virus capsid, STAC-BBB, for neurological disease targets, the companies said. The consideration for the deal includes a $20 million upfront license payment.
1
$Sangamo Therapeutics (SGMO.US)$
Late on posting this but here it is. I'm not trading again today, not focused on it anyways, maybe some quick in and outs.
Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
Positive
Secured $20 million upfront license fee from Astellas
Potential to earn up to $1.3 billion in additional fees and milestone payments
Will receive tiered mid-to-high single-digit royalties on potential net sales
N...
Late on posting this but here it is. I'm not trading again today, not focused on it anyways, maybe some quick in and outs.
Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
Positive
Secured $20 million upfront license fee from Astellas
Potential to earn up to $1.3 billion in additional fees and milestone payments
Will receive tiered mid-to-high single-digit royalties on potential net sales
N...
3
No comment yet
Andy-Lai : Envy.
WillLaw : Q2 25